Sino Biopharmaceutical Ltd (1177)
Hong Kong Stock Exchange · Hong Kong · prices in HKD · close of 22 Oct 2026
Key indicators
| Last close | HKD 4.980 |
|---|---|
| 52-week range | 4.190 – 7.490 |
| Return, 1 month / 3 months | −14.7% / −5.7% |
| Return, 1 year / 3 years | −29.1% / +97.8% |
| Trend | Below its 200-day average |
| RSI (14) | 37 |
| Volatility (1 year) | 41.6% |
| Worst drawdown (1 year) | -43.8% |
| Average daily value traded | 421.10M HKD |
| Dividend yield | 2.4% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Sino Biopharmaceutical is a pharmaceutical company that develops, makes and markets medicines, chiefly for patients in mainland China. Its products span several therapeutic areas, including treatments for hepatitis B and other liver diseases, oncology medicines, and a range of injectable and oral drugs used in hospitals. The company is based in Hong Kong and works through operating subsidiaries in China, supplying prescription medicines to hospitals and healthcare providers.
The shares are listed on the Hong Kong Stock Exchange in Hong Kong under the code 1177, and the price on this page is in Hong Kong dollars (HKD). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Sino Biopharmaceutical Ltd (1177) trades on the Hong Kong Stock Exchange in Hong Kong. It last closed at HKD 4.980 on 22 October 2026.
Its price-based Market X-Ray is 63 out of 100 (a fair price profile), ranking 736 of 2,611 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 29.1% and over the last three months it fell 5.7%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Hong Kong Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 62 · Fair | Mixed trend against its averages. | |
| Above 200-day average | -9.6% | ||
| From 52-week high | -32.4% | ||
| Momentum | 52 · Fair | Typical recent returns for this exchange. | |
| 3-month return | -5.7% | ||
| 6-month return | -12.5% | ||
| 12-month return, skipping the last month | -17.0% | ||
| Stability (higher is calmer) | 64 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 41.6% | ||
| Worst drawdown, 1 year (smaller is calmer) | -43.8% | ||
| Liquidity | 97 · Strong | Trades actively. | |
| Average daily value traded | 421.10M HKD | ||
| Zero-volume days | 0.0% | ||
| Income | 40 · Weak | Dividend is small or irregular. | |
| Dividend yield | 2.4% | ||
| Years with dividends | 5 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Income: Dividend is small or irregular.
Returns
| 1 week | −5.5% |
|---|---|
| 1 month | −14.7% |
| 3 months | −5.7% |
| 6 months | −12.5% |
| 1 year | −29.1% |
| 3 years | +97.8% |
| 5 years | −7.5% |
Signals
| 50-day / 200-day average | 5.406 / 5.508 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.255 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 1 Sep 2026 | HKD 0.0700 |
| 24 Jun 2026 | HKD 0.0500 |
| 29 Aug 2025 | HKD 0.0500 |
| 16 Jun 2025 | HKD 0.0400 |
| 10 Sep 2024 | HKD 0.0300 |
| 11 Jun 2024 | HKD 0.0300 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Hong Kong Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.